TY - JOUR
T1 - Strategies for relapsed peripheral T-cell lymphoma
T2 - The tail that wags the curve
AU - Lunning, Matthew A.
AU - Moskowitz, Alison J.
AU - Horwitz, Steven
N1 - Publisher Copyright:
© 2013 by American Society of Clinical Oncology.
PY - 2013/6/1
Y1 - 2013/6/1
N2 - A 69-year-old woman was referred for further evaluation and management of relapsed angioimmunoblastic T-cell lymphoma. At diagnosis, she received six cycles of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and achieved a complete response (CR). Her first surveillance computed tomography scan 3 months later demonstrated enlarging cervical lymphadenopathy. A lymph node excision confirmed relapsed angio-immunoblastic T-cell lymphoma with atypical lymphocytes expressing CD3, CD4, CD10, PD-1, and EBER, with loss of CD5(Fig1). A clonal T-cell receptor beta and gamma rearrangement by polymerase chain reaction was identical to that in her initial diagnostic biopsy. At our initial consultation, options for standard as well as investigational therapies were discussed, and HLA typing was initiated. The patient was enrolled onto an investigational phase II study; however, she developed progressive disease after two cycles. She was then treated with romidepsin 14mg/m2administered intravenously for 3 consecutive weeks with 1 week off. After two cycles, she achieved a partial response, and after four additional cycles, she maintained her response without further improvement. We discussed additional treatment options.
AB - A 69-year-old woman was referred for further evaluation and management of relapsed angioimmunoblastic T-cell lymphoma. At diagnosis, she received six cycles of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and achieved a complete response (CR). Her first surveillance computed tomography scan 3 months later demonstrated enlarging cervical lymphadenopathy. A lymph node excision confirmed relapsed angio-immunoblastic T-cell lymphoma with atypical lymphocytes expressing CD3, CD4, CD10, PD-1, and EBER, with loss of CD5(Fig1). A clonal T-cell receptor beta and gamma rearrangement by polymerase chain reaction was identical to that in her initial diagnostic biopsy. At our initial consultation, options for standard as well as investigational therapies were discussed, and HLA typing was initiated. The patient was enrolled onto an investigational phase II study; however, she developed progressive disease after two cycles. She was then treated with romidepsin 14mg/m2administered intravenously for 3 consecutive weeks with 1 week off. After two cycles, she achieved a partial response, and after four additional cycles, she maintained her response without further improvement. We discussed additional treatment options.
UR - http://www.scopus.com/inward/record.url?scp=84880728600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84880728600&partnerID=8YFLogxK
U2 - 10.1200/JCO.2012.48.3883
DO - 10.1200/JCO.2012.48.3883
M3 - Article
C2 - 23630204
AN - SCOPUS:84880728600
SN - 0732-183X
VL - 31
SP - 1922
EP - 1927
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 16
ER -